These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34714030)

  • 1. Effects of hemodialysis combined with calcitriol on cardiac function and BNP in nephrotic patients with secondary hyperparathyroidism.
    Wang H; Zhang C
    Minerva Surg; 2023 Oct; 78(5):587-589. PubMed ID: 34714030
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of hemodialysis combined with calcitriol on cardiac function and BNP in patients with hyperparathyroidism secondary to nephropathy.
    Shen J; Feng X; Li X
    Am J Transl Res; 2023; 15(4):2757-2764. PubMed ID: 37193143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
    Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK
    Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
    Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
    Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D.
    Nasif WA; Mukhtar MH; El-Emshaty HM; Alwazna AH
    Open Med Chem J; 2018; 12():98-110. PubMed ID: 30450134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
    Yuan F; Chen X; Wang C; Li Z; Liu H
    Blood Purif; 2018; 45(1-3):73-78. PubMed ID: 29216631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis].
    Szołkiewicz M; Zdrojewski Z; Sulima-Gillow A; Rutkowski B
    Przegl Lek; 1996; 53(5):427-30. PubMed ID: 8754407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients.
    Rodriguez M; Felsenfeld AJ; Williams C; Pederson JA; Llach F
    J Am Soc Nephrol; 1991 Nov; 2(5):1014-20. PubMed ID: 1760537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis.
    Lemmilä S; Saha H; Virtanen V; Ala-Houhala I; Pasternack A
    Am J Nephrol; 1998; 18(5):404-10. PubMed ID: 9730564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of calcitriol on secondary hyperparathyroidism].
    Xu H; Zhang J; Cheng X; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
    Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
    Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
    Tanaka M; Tokunaga K; Komaba H; Itoh K; Matsushita K; Watanabe H; Kadowaki D; Maruyama T; Otagiri M; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):161-8. PubMed ID: 21426509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
    Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
    Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of marked hyperphosphatemia during intravenous calcitriol therapy in hemodialysis patients with refractory hyperparathyroidism.
    Descombes E; Vogel G; Rosman J; Wauters JP
    Blood Purif; 1996; 14(3):234-41. PubMed ID: 8738537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.